Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Running title: pharmacogenetics of oral anticoagulant
نویسندگان
چکیده
1 INSERM, UMRS 490; University René Descartes, Paris, F-75270 France. 2 Assistance Publique Hôpitaux de Paris; Pharmacology Department, Bicêtre University Hospital, University Paris-Sud, Le Kremlin Bicêtre, France. 3 Assistance Publique Hôpitaux de Paris; Pharmacology Department, Saint Antoine University Hospital University Pierre et Marie Curie Paris 6, Paris, France. 4 INSERM, U525, Faculté de Médecine, Hôpital Pitié-Salpétrière, Paris, France. 5 Department of Immunology and Hematology, Saint-Antoine Hospital, 184 rue du Faubourg Saint Antoine 75012 Paris, France. 6 Clinical Investigation Center, Saint-Antoine Hospital, 75012 Paris, France 7 Assistance Publique Hôpitaux de Paris; Biochemistry Department, European Georges Pompidou Hospital, Paris, France. Correspondence: Blood First Edition Paper, prepublished online March 24, 2005; DOI 10.1182/blood-2005-01-0341
منابع مشابه
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability in the response to acenocoumarol among 222 healthy volunteers after a single oral dose. Associations between a pharmacodynamic index (reduction in factor VII activity and international normalized ratio [INR]...
متن کاملCytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability in the response to acenocoumarol among 222 healthy volunteers after a single oral dose. Associations between a pharmacodynamic index (reduction in factor VII activity and international normalized ratio [INR]...
متن کاملPharmacogenetics aspects of oral anticoagulants therapy
RATIONALE Vitamin K antagonists (VKA), such as warfarin and acenocoumarol, are widely used for the prevention and treatment of thromboembolic diseases and they are some of the most commonly prescribed types of medications. They are characterized by narrow therapeutic indices and inter-individual or intra-individual variability in response to the treatment. OBJECTIVE to establish the influence...
متن کاملAssociation between Cytochrome P450 2 C9 and Vitamin K Epoxide Reductase Complex Subunit 1 Polymorphisms with Warfarin dose among Iranian Patients
Background: Warfarin is a common anticoagulant drug that has a narrow therapeutic index; higher dose causes excessive bleeding and lower dose leads to cerebrovascular clotting and stroke in patients. Genetic factors that have been associated with warfarin response are the genes of cytochrome P450 2C9 (CYP2C9), which metabolize the more active S-enantiomer of warfarin, and vitamin K epoxide redu...
متن کاملClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ~50% of warfarin dose variability. The purpose of this article ...
متن کامل